URGN Q1 2022 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$927M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+81.2% YoY

Gross Profit

$12M88.8% margin

Operating Income

-$22M-161.9% margin

Net Income

-$28M-209.3% margin

EPS (Diluted)

$-1.25

QoQ Revenue Growth

-16.1%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$24M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$166M

Total Liabilities

$183M

Stockholders' Equity

-$17M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$7M	+81.2%
Gross Profit	$12M	$7M	+82.7%
Operating Income	-$22M	-$26M	+15.9%
Net Income	-$28M	-$26M	-9.5%

Revenue Segments

Jelmyto

$14M100%